Solving for Speed in Translational CMC

Wheeler’s vision pushes the boundaries of the CDMO model. By adding state-of-the-art, clinical drug substance manufacturing inside a venture studio in low-cost Oklahoma City, customers will benefit from reduced timelines, reduced regulatory risks, and reduced costs

Register Free: https://www.biopharminternational.com/bp_w/solving-for-speed

Event Overview:

Hear how Dr. Jesse McCool, Co-Founder and CEO of Wheeler Bio, is building a disruptive CDMO asset inside Oklahoma City based venture studio, Echo Investment Capital. Wheeler’s model is designed to expedite translational CMC while solving for client timelines and budget along the way to first-in-human studies. Their lead service offering, Portable CMC™, is an open-source, predictive, “CMC middleware” that efficiently bridges discovery and CGMP. Wheeler’s own CGMP drug substance capacity comes on-line in Q3.

Key Learning Objectives

• Learn about Wheeler Bio’s focused strategy for serving the emerging biotech market.
• Learn how Wheeler Bio is connecting technology, equipment, with automation and rapid CMC concepts.
• Learn how Wheeler Bio is using predictive modeling, machine learning, and digital twins to provide tangible benefits to emerging biotech companies.

Who Should Attend

• Drug developers
• Venture portfolio managers
• Process engineers
• Process scientists
• Cell line development scientists
• CMC consultants
• Protein scientists

Speaker:

Jesse McCool
Co-Founder and Chief Executive Officer
Wheeler Bio, Inc

Dr. Jesse McCool is the Co-Founder and CEO of Wheeler Bio, an agile, small-batch biologics drug substance manufacturer focused on addressing unmet needs in the translational space. He has over 20 years of biologics development and manufacturing experience in biotech and CDMO environments. He previously held executive and technical positions at Cytovance Biologics, Lonza, Lallemand/Mascoma, Dartmouth, and Clean Harbors. He joined Cytovance Biologics in 2013 to build out and lead the process development organization. The company was acquired by Hepalink in 2015 after which he was named Director, Chief Technical Officer and eventually, Chief Executive Officer. Jesse left Hepalink following the successful HK IPO in 2020 ($500MM USD) to join OKC-based venture studio, Echo Investment Capital, as Entrepreneur-In-Residence. He co-founded and launched Wheeler Bio in 2021. He also serves on the Governor's Council for Workforce and Economic Development (State Commerce) and works on numerous workforce development initiatives in the biomanufacturing sector. Jesse earned a Ph.D. from the University of Massachusetts at Amherst and completed his postdoctoral work at Dartmouth (Hanover, NH) and Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher, and peer-reviewed journal author and contributor.

Register Free: https://www.biopharminternational.com/bp_w/solving-for-speed